SB0114 amends Utah’s controlled substances schedules in Section 58-37-4. The bill largely updates the state’s list of Schedule I through V substances, including a wide range of opioids, stimulants, depressants, hallucinogens, anabolic steroids, and other listed drugs. It also makes a targeted change to psilocybin: crystalline polymorph psilocybin would be automatically rescheduled in Utah if the federal government reschedules that specific pharmaceutical composition into a schedule other than Schedule I.
The bill also preserves and clarifies several existing federal-conformity provisions for certain FDA-approved marijuana-related drug products and other controlled-substance formulations. It does not appropriate money and contains no special clauses beyond the substantive scheduling changes and an effective date of May 6, 2026.
Impact
SB0114 would directly amend Utah Code Section 58-37-4, which governs the state’s controlled substance schedules. Its practical effect is to keep Utah’s drug schedules aligned with federal scheduling in a limited way for crystalline polymorph psilocybin, while also maintaining the state’s detailed listing of controlled substances and related exceptions for certain approved pharmaceutical products. The bill affects law enforcement, regulators, pharmacists, prescribers, manufacturers, and anyone handling substances listed in the schedules, especially those involving psilocybin and marijuana-derived FDA-approved medications.
Sentiment
Based on the available record, the bill appears to have been introduced without recorded committee debate or vote history in the provided materials, so there is no documented public sentiment from transcripts or roll calls. The text itself suggests a technical, conformity-focused approach rather than a broad policy shift, which typically indicates a neutral or administrative legislative posture. Because the bill was filed and no votes are shown, there is no evidence here of organized support or opposition in the available context.
Contention
The main potential point of contention is the psilocybin provision. By providing for automatic rescheduling of crystalline polymorph psilocybin if the federal government reschedules it, the bill ties Utah law to future federal action, which may concern lawmakers who prefer state-level control over drug policy. More broadly, the extensive controlled-substances list includes substances associated with opioid enforcement, cannabis, psychedelics, and prescription sedatives, but the bill text does not show any specific dispute over those listings in the available record.